Compare BFC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFC | NUVB |
|---|---|---|
| Founded | 1894 | 2018 |
| Country | United States | United States |
| Employees | N/A | 298 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2018 | N/A |
| Metric | BFC | NUVB |
|---|---|---|
| Price | $139.91 | $5.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $157.00 | $11.38 |
| AVG Volume (30 Days) | 78.1K | ★ 3.8M |
| Earning Date | 04-16-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 11.23 | N/A |
| EPS | ★ 1.78 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.67 | $203.82 |
| Revenue Next Year | $2.01 | $58.18 |
| P/E Ratio | $76.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $109.11 | $1.57 |
| 52 Week High | $153.00 | $9.75 |
| Indicator | BFC | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 46.14 | 65.42 |
| Support Level | $119.60 | $5.22 |
| Resistance Level | $140.93 | $5.55 |
| Average True Range (ATR) | 3.78 | 0.31 |
| MACD | -0.59 | 0.06 |
| Stochastic Oscillator | 44.14 | 99.62 |
Bank First Corp is a United States-based company engaged in providing financial services, a full range of consumer and commercial financial institution services to individuals and businesses, including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.